Literature DB >> 12604309

Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice.

Déborah Braun1, Pedro Geraldes, Jocelyne Demengeot.   

Abstract

Type I Interferons (IFN-I) are immunoregulatory cytokines that enhance activation and survival of many cellular components of the immune system. In the present work, we evaluated the effect of IFN-I on the development of the lymphoproliferative disorder in Fas-defective lpr mice. We report that sustained injection of polyinosinic:polycytidylic acid, a potent inducer of IFN-I, in B6 lpr mice resulted in a dramatic aggravation of the renal disease, higher titers of autoantibodies, a 10-fold increase in serum Ig and accumulation of activated lymphocytes. Moreover, introducing a null mutation for the IFN-I-Receptor gene into the lpr background resulted in dramatic decrease of immune complexes deposition in the kidney and reduced lymphadenopathy. While several recent reports correlated serum levels of IFN-alpha with disease activity in systemic Lupus erythematosus patients, our findings establish a causal link from IFN-I production to the onset and severity of another related autoimmune syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604309     DOI: 10.1016/s0896-8411(02)00109-9

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  65 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

2.  Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation.

Authors:  L A O'Reilly; P Hughes; A Lin; P Waring; U Siebenlist; R Jain; D H D Gray; S Gerondakis; A Strasser
Journal:  Cell Death Differ       Date:  2014-10-31       Impact factor: 15.828

Review 3.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

Review 4.  Understanding the development and function of T follicular helper cells.

Authors:  Roza I Nurieva; Yeonseok Chung
Journal:  Cell Mol Immunol       Date:  2010-04-12       Impact factor: 11.530

Review 5.  Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.

Authors:  Sean R Christensen; Mark J Shlomchik
Journal:  Semin Immunol       Date:  2007-02-02       Impact factor: 11.130

6.  CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Lijun Zhang; Vasileios C Kyttaris; George C Tsokos; Isaac E Stillman; Takaharu Ichimura; Joseph V Bonventre; Peter Libby; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

7.  Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery.

Authors:  Jessica K Gordon; Cynthia Magro; Theresa Lu; Robert Schneider; April Chiu; Richard R Furman; Garron Solomon; Anne Bass; Doruk Erkan
Journal:  HSS J       Date:  2009-07-16

8.  Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus.

Authors:  Roberto Baccala; Rosana Gonzalez-Quintial; Amanda L Blasius; Ivo Rimann; Keiko Ozato; Dwight H Kono; Bruce Beutler; Argyrios N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 9.  Sexual dimorphism in autoimmunity.

Authors:  Kira Rubtsova; Philippa Marrack; Anatoly V Rubtsov
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

10.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.